Expanded Access Program for ibalizumab in Resistant HIV-1

This Expanded Access Program provides ibalizumab, an investigational new drug, for eligible patients with resistant HIV-1.

EAP STUDY LOCATIONS
Additional study locations may be added. To inquire about participating as a new study location, please call 240-453-2658.
To request more information about this EAP or to enroll
patients, call 240-453-2658 or Email us.